Search

Itchy skin, a symptom of various diseases, present in 54.4 % of patients with skin pathologies, is a rather difficult task when choosing a therapy.Material and methods. Under observation were 45 patients (27 women and 18 men) with various dermatoses, accompanied by itching. All patients received Neotanin therapy (cream and spray) with standard topical therapy. Efficiency assessment was carried out taking into account the indices Prurindex, BRS, dermatological status indices for each nosology (SCORAD, EASI, PASI), and DIC.Results. In patients with idiopathic skin itching, Prurindex decreased by 100 % by the end of 3rd weeks, BRS – by 96.8 %. In atopic dermatitis, the SCORAD index decreased by 78.3 %, BRS index reduced by 91.9 %, Prurindex index decreased by 95.4 %. With eczema, the EASI index decreased by 96.1 %, the BRS and Prurindex index were reduced by 100 %. In psoriasis, the PASI index decreased by 86.5 %, BRS index – by 90.8 %, Prurindex index – by 94.2 %.Conclusions. The use of the topical Neotanin as monotherapy for idiopathic pruritus, as a part of comprehensive treatment for atopic dermatitis, eczema, psoriasis, significantly improves the quality of life of patients.

Currently, the ongoing pandemic of the novel coronavirus infection is still a major public health problem worldwide. The questions of immunosuppressive therapy of patients with psoriasis and psoriatic arthritis, the possibility of vaccination against the background of the use of genetically engineered drugs remain open. The article is of an overview nature and includes up-to-date information on the feasibility and safety of the use of genetically engineered biological drugs in patients with psoriasis in a pandemic (COVID-19). According to the international recommendations of the National Psoriasis Foundation COVID-19 Task Force expert group, treatment of psoriasis and/or PsA does not significantly alter the risk of SARS-CoV-2 infection and does not lead to worse prognosis of COVID-19. Therefore, patients not infected with SARS-CoV-2 should continue biological or other systemic therapy for psoriasis and/or PsA. According to a registry from 25 countries, hospitalization with SARS-CoV-2 infection was more common in patients receiving nonbiological systemic therapy than in patients receiving BAs. Thus, genetically engineered biological drugs do not appear to cause an increased risk of coronavirus infection and do not determine a more severe course. With regard to vaccination of patients with psoriasis, many issues require further study. According to international agreements, vaccination is not contraindicated in patients with psoriatic disease. However, there is still insufficient data on how the treatment of psoriatic disease affects vaccination. Avoiding COVID-19 or reducing the severity of infection following SARS-CoV-2 vaccination is thought to far outweigh any risk directly related to vaccination complications.

Here, we performed the comprehensive review of the peer-reviewed literature of the effect of chronic foci of streptococcal infection on the course of skin psoriasis, as well as an assessment of the effectiveness of tonsillectomy on the course of this pathology. A PubMed, Web of Science and Google Scholar search were performed with the keywords 'psoriasis' AND 'tonsillectomy' OR 'tonsillitis' OR 'streptococcal infection'. The reviewers identified and evaluated 197 reports published prior to August 2018, of which 153 were excluded from further analysis after review of titles and/or abstracts including four duplicate studies from the same authors in the same patient groups. In total, 44 reports were used and included in the review (including original studies, a description of clinical cases, literature reviews). Analysis of the original studies showed that the effectiveness of tonsillectomy in patients with psoriasis is from 11.4 to 78.6%. Among clinical cases, the rate was 20-100%. We did not conduct a meta-analysis and use the statistical methods because of the heterogeneity of the data. Data were analysed using a descriptive approach. Most studies came from Russia, USA, Japan. However, multiple limitations in the studies do not allow final conclusions about the effectiveness of tonsillectomy in patients with psoriasis.Цель данного обзора - всесторонний систематический обзор рецензируемых данных литературы, касающихся влияния хронических очагов стрептококковой инфекции на течение псориаза кожи, а также оценка эффективности тонзиллэктомии на течение данной патологии. Проведен поиск в базах данных PubMed, Web of Science, Google Scholar по ключевым словам 'psoriasis' AND 'tonsillectomy' OR 'tonsillitis' OR 'streptococcal infection'. Было обнаружено 197 публикаций на период до августа 2018 г. Метаанализ не был проведен из-за неоднородности данных. При изучении информации использовался описательный подход. Были исключены 153 публикации в связи с нерелевантностью данных. Всего в анализ было включено 44 публикации (в том числе оригинальные исследования, описание клинических случаев, обзоры литературы). Нами было изучено 25 публикаций на тему эффективности тонзиллэктомии у больных псориазом (без учета обзоров литературы). Всего в обзор было включено 10 оригинальных исследований, 15 клинических случаев и серий клинических наблюдений. Анализ оригинальных исследований показал, что эффективность тонзиллэктомии у больных псориазом варьирует от 11,4 до 78,6%. Среди клинических случаев показатель был 20-100%. Наибольшее количество исследований проведено в России, США, Японии. Тем не менее множественные ограничения в исследованиях не позволяют делать окончательные выводы об эффективности тонзиллэктомии у пациентов с псориазом.